Compound class:
Synthetic organic
Comment: LPC-233 is an orally bioavailable preclinical antibacterial compound that inhibits bacterial UDP-3-O-acyl-N-acetylglucosamine deacetylase (LpxC) and has potent activity against a wide range of Gram-negative bacteria in vitro [5].
|
|
Bioactivity Comments |
LPC-233 has potent Gram-negative antibacterial activity in vitro, with MIC90 values in the range of 0.032-1 μg/ml against a collection of clinical isolates including extensively drug resisistant (XDR) strains of Pseudomonas aeruginosa, but does not have detectable activity against Gram-positive bacteria [5]. |